Literature DB >> 19372901

Antiretroviral therapy-induced liver alterations.

Ulrich A Walker1.   

Abstract

PURPOSE OF REVIEW: Antiretroviral drugs are associated with hepatotoxicity. Progress in our knowledge on the prevalence, contributory factors and mechanisms is reviewed. RECENT
FINDINGS: Liver toxicity is highly prevalent and a major cause of hospitalization among HIV-infected individuals. Liver steatosis is probably more frequent in the setting of hepatitis C virus coinfection but is also seen in noncoinfected patients. Among the individual drugs, severe liver toxicity is more strongly associated with nevirapine, and the mitochondrial toxicity of some nucleoside analogues. Mitochondrial toxicity can also induce or contribute to steatohepatitis, with dietary uridine supplementation as a possible strategy of prevention. Atazanavir inhibits UDP-glucuronosyltransferase, which in Gilberts' syndrome has been associated with breast cancer. A UDP-glucuronosyltransferase gene promoter variant predisposes to hyperbilirubinemia. Tipranavir induces elevated transaminases more frequently than boosted comparator protease inhibitors. CCR5 inhibitors may predispose to hepatotoxic events by causing an imbalance in the cytokine response.
SUMMARY: Hepatotoxicity is associated with all classes of antiretroviral agents and continues to contribute to hospitalization.

Entities:  

Year:  2007        PMID: 19372901     DOI: 10.1097/COH.0b013e328122dbaa

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  7 in total

1.  Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.

Authors:  F Ortu; L E Weimer; Marco Floridia; P E Manconi
Journal:  Eur J Med Res       Date:  2010-02-26       Impact factor: 2.175

2.  Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study.

Authors:  José Antonio Mata-Marín; Jesús Gaytán-Martínez; Bernardo Horacio Grados-Chavarría; José Luis Fuentes-Allen; Carla Ileana Arroyo-Anduiza; Alfredo Alfaro-Mejía
Journal:  Virol J       Date:  2009-10-30       Impact factor: 4.099

3.  Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Authors:  Zelalem Petros; Ming Ta Michael Lee; Atsushi Takahashi; Yanfei Zhang; Getnet Yimer; Abiy Habtewold; Ina Schuppe-Koistinen; Taisei Mushiroda; Eyasu Makonnen; Michiaki Kubo; Eleni Aklillu
Journal:  OMICS       Date:  2017-04

4.  Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

Authors:  Getnet Yimer; Nobuhisa Ueda; Abiy Habtewold; Wondwossen Amogne; Akira Suda; Klaus-Dieter Riedel; Jürgen Burhenne; Getachew Aderaye; Lars Lindquist; Eyasu Makonnen; Eleni Aklillu
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

5.  Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.

Authors:  Getnet Yimer; Marcus Gry; Wondwossen Amogne; Eyasu Makonnen; Abiy Habtewold; Zelalem Petros; Getachew Aderaye; Ina Schuppe-Koistinen; Lars Lindquist; Eleni Aklillu
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

6.  Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study.

Authors:  Alima Hassen Ali; Tefera Belachew; Alemeshet Yami; Wubeante Yenet Ayen
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

7.  Risk Factors for Alanine Aminotransferase Elevations in a Prospective Cohort of HIV-Infected Tanzanian Adults Initiating Antiretroviral Therapy.

Authors:  Sabina F Mugusi; David Sando; Ferdinand M Mugusi; Claudia Hawkins; Said Aboud; Wafaie W Fawzi; Christopher R Sudfeld
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.